David Scheer

David Scheer serves as the Chairman of the Board for OrphAI Therapeutics, Adela, Inc., Refactor Health, and BiologicsMD, Inc., holding these positions since July 2023, June 2020, September 2020, and January 2020, respectively. Additionally, David Scheer has been the President of Scheer & Company, Inc. since 1981. Previous leadership roles include Chairman of the Board of Directors at Revelar Biotherapeutics until October 2022, Director and Chair of the Board at Achilion Pharmaceuticals until February 2020, and Chairman for multiple companies, including ArRETT Neuroscience, Achillion Pharmaceuticals (2008-2018), and Axerion Therapeutics until April 2017. David Scheer holds an AB, cum laude, in Biochemical Sciences from Harvard University and an M.S. in Cell, Molecular, and Developmental Biology from Yale University.